SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tomoyoshi Kondo, Yoshikuni Mizuno, A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease, Clinical Neuropharmacology, 2015, 38, 2, 41

    CrossRef

  2. 2
    Eero Rissanen, Jouni Tuisku, Pauliina Luoto, Eveliina Arponen, Jarkko Johansson, Vesa Oikonen, Riitta Parkkola, Laura Airas, Juha O Rinne, Automated reference region extraction and population-based input function for brain [11C]TMSX PET image analyses, Journal of Cerebral Blood Flow & Metabolism, 2015, 35, 1, 157

    CrossRef

  3. 3
    Yingqun Tao, Guobiao Liang, Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials, Cell Biochemistry and Biophysics, 2015, 71, 1, 57

    CrossRef

  4. 4
    Delia Preti, Pier Giovanni Baraldi, Allan R. Moorman, Pier Andrea Borea, Katia Varani, History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents, Medicinal Research Reviews, 2015, 35, 3
  5. 5
    Ashish Kumar Kakkar, Neha Dahiya, Management of Parkinson׳s disease: Current and future pharmacotherapy, European Journal of Pharmacology, 2015, 750, 74

    CrossRef

  6. 6
    Shin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets, European Journal of Pharmacology, 2015, 747, 160

    CrossRef

  7. 7
    Angelo Antonini, Werner Poewe, Adenosine A2A receptor antagonists in Parkinson's disease: still in the running, The Lancet Neurology, 2014, 13, 8, 748

    CrossRef

  8. 8
    Annalisa Pinna, Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued, CNS Drugs, 2014, 28, 5, 455

    CrossRef

  9. 9
    Luca Antonioli, Balázs Csóka, Matteo Fornai, Rocchina Colucci, Endre Kókai, Corrado Blandizzi, György Haskó, Adenosine and inflammation: what's new on the horizon?, Drug Discovery Today, 2014, 19, 8, 1051

    CrossRef

  10. 10
    Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox, Emerging drugs for levodopa-induced dyskinesia, Expert Opinion on Emerging Drugs, 2014, 19, 3, 415

    CrossRef

  11. 11
    Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gian Filippo Antoninetti, Rafael Franco, José Luis Lanciego, Younis Baqi, Christa E. Müller, Annalisa Pinna, Fabio Blandini, Marie Therese Armentero, Neuroprotective Potential of Adenosine A2A and Cannabinoid CB1 Receptor Antagonists in an Animal Model of Parkinson Disease, Journal of Neuropathology & Experimental Neurology, 2014, 73, 5, 414

    CrossRef

  12. 12
    Anne-Catherine Vijverman, Susan H Fox, New treatments for the motor symptoms of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 761

    CrossRef

  13. 13
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  14. 14
    Izaskun Villar-Menéndez, Fabiana Nuñez, Sara Díaz-Sánchez, José Luis Albasanz, Jaume Taura, Víctor Fernández-Dueñas, Isidre Ferrer, Mairena Martín, Francisco Ciruela, Marta Barrachina, Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation, Purinergic Signalling, 2014, 10, 3, 523

    CrossRef

  15. 15
    Shin-ichi Uchida, Tomomi Tashiro, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of L-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets, Journal of Pharmacological Sciences, 2014, 124, 4, 480

    CrossRef

  16. 16
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  17. 17
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  18. 18
    Adolfo Ramirez-Zamora, Eric Molho, Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions, Expert Review of Neurotherapeutics, 2014, 14, 1, 93

    CrossRef

  19. 19
    Albert Y. Hung, Michael A. Schwarzschild, Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?, Neurotherapeutics, 2014, 11, 1, 34

    CrossRef

  20. 20
    Santiago Perez-Lloret, Marcelo Merello, Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant, Expert Opinion on Pharmacotherapy, 2014, 15, 8, 1097

    CrossRef

  21. 21
    Joanne Bronson, Amelia Black, Murali Dhar, Bruce Ellsworth, J. Robert Merritt, 2014,

    CrossRef

  22. 22
    Peter Jenner, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  23. 23
    Akihisa Mori, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  24. 24
    Masahiro Nomoto, Masahiro Nagai, Noriko Nishikawa, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  25. 25
    Masahiko Tomiyama, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  26. 26
    Tomoyuki Kanda, Shin-ichi Uchida, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  27. 27
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  28. 28
    Susan H. Fox, Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease, Drugs, 2013, 73, 13, 1405

    CrossRef

  29. 29
    Carlos Zúñiga-Ramírez, Federico Micheli, Preladenant: an adenosine A2Areceptor antagonist for Parkinson’s disease, Future Neurology, 2013, 8, 6, 639

    CrossRef